Risankizumab as induction therapy for Crohn's disease: results ...
Risankizumab, an IL-23 p19 inhibitor, showed efficacy and safety in treating moderately to severely active Crohn's disease in phase 3 trials ADVANCE and MOTIVATE. Patients receiving risankizumab achieved higher clinical remission and endoscopic response rates at week 12 compared to placebo, with similar adverse event rates across groups.
Related Clinical Trials
Reference News
Risankizumab as induction therapy for Crohn's disease: results ...
Risankizumab, an IL-23 p19 inhibitor, showed efficacy and safety in treating moderately to severely active Crohn's disease in phase 3 trials ADVANCE and MOTIVATE. Patients receiving risankizumab achieved higher clinical remission and endoscopic response rates at week 12 compared to placebo, with similar adverse event rates across groups.